On September 9^th, the U.S. House of Representatives passed the BIOSECURE Act and now heads to the Senate. The bill would prohibit contracting with certain Chinese biotechnology companies deemed potential national security risks, specifically BGI, MGI, Complete Genomics, WuXi AppTec and WuXi Biologics.
 
The legislation gives U.S. drugmakers contracting with these companies until 2032 to terminate contracts and find new service providers.
 
If passed, concerns remain that the bill could further strain the U.S. supply chain.
 
In January of this year, the U.S. House Select Committee introduced the BIOSECURE Act to prevent Chinese biotechnology companies from accessing U.S. funding and collaborating with pharma companies. The bill aims to safeguard personal health and genetic information of Americans from foreign adversaries.

Further reading: 
U.S. Lawmakers Seek Sanctions on WuXi AppTec, WuXi Biologics

U.S. Legislation Seeking Sanctions on BGI, WuXi Apptec Advances

U.S. Biosecure Act Advances with Revised Timeline